However, a network meta-analysis of randomized trials of antihypertensive medication observed that only angiotensin-converting enzyme inhibitors and angiotensin receptor blockers reduced diabetes risk (20), suggesting it is renin-angiotensin system (RAS) activation that is causally related to risk of new-onset diabetes and not BP per se. Here, REN is linked to diabetes mellitus.